An Expanded Access Program for Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
NCT ID: NCT04256265
Last Updated: 2020-10-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
APPROVED_FOR_MARKETING
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
NCT05232929
EAP of Apitegromab for Patients With Spinal Muscular Atrophy
NCT06877689
Home Monitoring of Adult Patients With SMA: a Pilot Multicenter Validation Study
NCT05839145
Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)
NCT02865109
A Study of CK-2127107 in Patients With Spinal Muscular Atrophy
NCT02644668
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Risdiplam
Risdiplam will be administered orally once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Not eligible for treatment with currently approved treatments for SMA, or cannot continue treatment with currently approved medications as documented by the treating physician, or in the treating physician's judgment, the participant is at risk of lack/loss of treatment efficacy of the current therapy.
* The participant does not qualify for and has no access to SMA treatment in the context of an ongoing clinical trial.
* Adequately recovered from any acute illness at the time of screening, and considered clinically well enough to participate, in the opinion of the treating physician.
* Participants with retinopathy of prematurity should have evidence of stable disease.
Type 1 SMA Participants:
\- Confirmed diagnosis of 5q-autosomal recessive SMA.
Type 2 SMA Participants:
* Confirmed diagnosis of 5q-autosomal recessive SMA.
* Negative blood pregnancy test at screening (all women of childbearing potential, including those who have had a tubal ligation), and agreement to comply with measures to prevent pregnancy and restrictions on egg and sperm donation.
* Males with female partners of reproductive potential must agree to use highly effective contraception during therapy, and for at least 4 months after treatment discontinuation.
Exclusion Criteria
* Concomitant or previous participation in any investigational drug or device study within 90 days prior to screening or 5 half-lives, whichever is longer.
* Administration of other SMN-2 targeting therapy within 120 days of starting risdiplam therapy.
* Administration of SMA gene therapy within the last 3 months (12 weeks) of receiving risdiplam therapy.
* Any serious medical condition, treatment, or abnormality in clinical laboratory tests that, in the treating physician's judgment, precludes the participant's safe participation in the program.
* Ascertained or presumptive hypersensitivity (e.g., anaphylactic reaction) to risdiplam or to the constituents of its formulation.
* Suspicion of illicit drug or alcohol abuse, in the treating physician's judgment.
* Any prior use of an inhibitor or inducer of flavin-containing monooxygenases 1 (FMO1) or flavin-containing monooxygenases 3 (FMO3) taken within 2 weeks (or within 5 times the elimination half-life, whichever is longer) prior to dosing.
2 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genentech, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arkansas Children's Hospital; Pediatrics
Little Rock, Arkansas, United States
Children's Hospital Los Angeles
Los Angeles, California, United States
Stanford University
Palo Alto, California, United States
University of Colorado in Denver-Anschutz Medical Campus
Aurora, Colorado, United States
Nemours Children's Hospital
Orlando, Florida, United States
Comprehensive NeuroBehavioral Institute
Plantation, Florida, United States
Rare Disease Research, LLC
Atlanta, Georgia, United States
Ann and Robert H. Lurie Children Hospital of Chicago
Chicago, Illinois, United States
Southern Illinois University, School of Medicine
Springfield, Illinois, United States
Indiana Hemophilia & Thrombosis center
Indianapolis, Indiana, United States
University of Iowa
Iowa City, Iowa, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
University of Louisville
Louisville, Kentucky, United States
Massachusetts General Hospital; Neurology
Boston, Massachusetts, United States
Helen DeVos Children's Hospital at Spectrum Health
Grand Rapids, Michigan, United States
University of Mississippi Medical Center; Neurology
Jackson, Michigan, United States
Gillette Spcl Children's Clin; Pediatric Endocrinology
Saint Paul, Minnesota, United States
St. Louis Children Hospital
St Louis, Missouri, United States
Goryeb Children's Hospital
Morristown, New Jersey, United States
Northwell Hospital
New Hyde Park, New York, United States
NYU Langone
New York, New York, United States
University of Rochester Medical Center
Rochester, New York, United States
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States
Akron Childrens Hospital
Akron, Ohio, United States
Nationwide Children's Hospital
Columbus, Ohio, United States
University of Virginia Children's Hospital; Developmental
Charlottesville, Virginia, United States
University of Wisconsin American Family; Childrens Hospital
Madison, Wisconsin, United States
Childrens Hospital of Wisconsin
Milwaukee, Wisconsin, United States
Medical College of Wisconsin, Inc.
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kwon JM, Arya K, Kuntz N, Phan HC, Sieburg C, Swoboda KJ, Veerapandiyan A, Assman B, Bader-Weder S, Dickendesher TL, Hansen J, Lin H, Yan Y, Rao VK; US Expanded Access Program Working Group. An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy. Ann Clin Transl Neurol. 2022 Jun;9(6):810-818. doi: 10.1002/acn3.51560. Epub 2022 May 14.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AL41887
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.